MT
MTHRY.US M3 Inc
- Market cap
- USD 7.56B
- P/E
- 25.9x
- P/B
- 2.97x
- ROE
- 9.8%
- Dividend yield
- 1.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MTHRY.US undervalued?
Graham numberMTHRY.US trades 84.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
M3 Inc fundamental analysis
No fundamental analysis for M3 Inc yet.
M3 Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About M3 Inc
M3, Inc. provides medical-related services to physicians and other healthcare professionals through the internet. It operates m3.com, a members-only website for providing information, tools, and services for medical professionals; MR-kun which delivers the latest medical information for daily medical practice; QOL-kun, a marketing support service that provides selected information useful for doctors; m3.com CAREER, a physician recruitment and career change support site; and …
Full company profileM3 Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
M3 Inc annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 78.1B | 94.5B | 113B | 131B | 169B | 208B | 231B | 239B | 285B | 373B | 366B |
| Gross Profit | 45.4B | 53.0B | 62.9B | 69.8B | 99.3B | 118B | 129B | 141B | 154B | 186B | 180B |
| Operating Income | 24.0B | 26.9B | 27.8B | 34.3B | 58.4B | 95.1B | 72.0B | 65.5B | 63.0B | 74.3B | 65.1B |
| EBITDA | 24.8B | 28.2B | 29.2B | 39.1B | 64.6B | 73.6B | 77.8B | 74.5B | 77.7B | 92.6B | 73.8B |
| Net Income | 16.0B | 18.1B | 19.6B | 21.6B | 37.8B | 63.8B | 49.0B | 45.3B | 40.5B | 52.1B | 40.2B |
| EPS | 12 | 14 | 15 | 16 | 28 | 47 | 36 | 33 | 30 | 38 | 30 |
| Balance Sheet | |||||||||||
| Total Assets | 95.5B | 116B | 137B | 222B | 273B | 346B | 401B | 491B | 582B | 640B | 662B |
| Total Liabilities | 26.0B | 31.3B | 35.0B | 50.2B | 65.9B | 82.0B | 91.1B | 124B | 169B | 192B | 214B |
| Shareholders' Equity | 67.1B | 82.5B | 98.7B | 166B | 200B | 258B | 303B | 352B | 378B | 410B | 409B |
| Cash & Short-term Investments | 21.1B | 24.8B | 30.5B | 82.6B | 115B | 141B | 146B | 180B | 167B | 157B | 147B |
| Total Debt | - | - | - | 6.09B | 5.42B | 8.30B | 10.4B | 18.5B | 24.4B | 33.3B | 36.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.6B | 15.9B | 17.7B | 26.8B | 46.6B | 52.1B | 57.1B | 58.3B | 51.7B | 74.5B | - |
| Capital Expenditure | 774M | 1.85B | 1.35B | 2.84B | 1.99B | 3.22B | 7.58B | 7.58B | 8.99B | 8.14B | 0.00 |
| Free Cash Flow | 15.8B | 14.1B | 16.4B | 23.9B | 44.6B | 48.9B | 49.5B | 50.7B | 42.8B | 66.4B | - |
| Ratios | |||||||||||
| ROE | 23.9% | 22.0% | 19.8% | 13.0% | 18.9% | 24.8% | 16.2% | 12.9% | 10.7% | 12.7% | 9.8% |
| ROA | 16.8% | 15.6% | 14.3% | 9.8% | 13.8% | 18.5% | 12.2% | 9.2% | 7.0% | 8.1% | 6.1% |
| Net Profit Margin | 20.5% | 19.2% | 17.3% | 16.5% | 22.4% | 30.7% | 21.2% | 19.0% | 14.2% | 14.0% | 11.0% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | 0.03x | 0.03x | 0.05x | 0.06x | 0.08x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
M3 Inc dividends
- Dividend yield
- 1.21%
- Forward dividend
- 0.07 USD
- Payout ratio
- 29.0%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 15.1B | 11 | 29.0% |
| 2025 | JPY 14.3B | 10 | 35.2% |
| 2024 | JPY 12.9B | 9.49 | 28.5% |
| 2023 | JPY 10.9B | 7.99 | 22.2% |
| 2022 | JPY 8.14B | 5.99 | 12.8% |
| 2021 | JPY 5.77B | 4.25 | 15.3% |
| 2020 | JPY 4.53B | 3.34 | 21.0% |
| 2019 | JPY 3.35B | 2.59 | 17.1% |
| 2018 | JPY 3.24B | 2.50 | 17.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns M3 Inc
- Insiders 0.00%
- Institutions 0.04%
- Public & others 99.96%
- Shares outstanding 1.33B
- Free float 661M
M3 Inc company profile
- Company name
- M3 Inc
- Ticker
- MTHRY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 17,010
- Fiscal year end
- March
- Address
- Akasaka Intercity, Tokyo, Japan, 107-0052
- Phone
- 81 3 6229 8900
- Website
- corporate.m3.com
About M3 Inc
M3, Inc. provides medical-related services to physicians and other healthcare professionals through the internet. It operates m3.com, a members-only website for providing information, tools, and services for medical professionals; MR-kun which delivers the latest medical information for daily medical practice; QOL-kun, a marketing support service that provides selected information useful for doctors; m3.com CAREER, a physician recruitment and career change support site; and Yakucari, a job search website for pharmacists. The company also provides online lectures; clinical trial; research targeting domestic medical professionals; medical-related self-planned data and research reports; global health professional research; survey panel provision services; and m3.com opening and management services. In addition, it offers AskDoctors, where registered doctors answer questions about health and illness from the public; MDLinx for medical professionals in the United States; and Doctors.net.uk, a website that provides services for pharmaceutical companies; and drug information database. Further, the company is involved in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; Support for recruiting subjects necessary for clinical development and clinical research, and related tasks; provision of management support to medical institutions, as well as visiting nursing, day care, and home care support services; and operates podiatry and venous disease clinics, and hospice facilities. Additionally, it offers clinical and medico-political news and education for medical professionals. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
M3 Inc management
1- Mr. Itaru TanimuraPresident & Chairman · born 1965